

1 Targeted control of pneumolysin production by a mobile genetic 2 element in *Streptococcus pneumoniae*.

3
4 Emily J. Stevens^{1*}, Daniel J. Morse^{1*}, Dora Bonini^{1*}, Seána Duggan¹, Tarcisio Brignoli¹,
5 Mario Recker², John A. Lees³, Nicholas J. Croucher³, Stephen Bentley⁴, Daniel J. Wilson⁵,
6 Sarah G. Earle⁵, Robert Dixon⁵, Angela Nobbs⁶, Howard Jenkinson⁶, Tim van Opijnen⁷,
7 Derek Thibault⁷, Oliver J. Wilkinson⁸, Mark S. Dillingham⁸, Simon Carlile⁹, Rachel M.
8 McLoughlin⁹, and Ruth C. Massey^{1,10,§}.

9
10 **1:** School of Cellular and Molecular Medicine, University of Bristol, Bristol, BS8 1TD, UK.
11 **2:** Centre for Ecology and Conservation, University of Exeter, Penryn Campus, TR10 9FE,
12 UK.
13 **3:** MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease
14 Epidemiology, St. Mary's Campus, Imperial College London, London, W2 1PG, UK.
15 **4:** The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton,
16 Cambridge CB10 1SA, UK.
17 **5:** Big Data Institute, Nuffield Department of Population Health, University of Oxford, Oxford
18 OX3 7LF, UK.
19 **6:** Bristol Dental School, University of Bristol, Bristol, BS1 2LY, UK.
20 **7:** Biology Department, Boston College, Chestnut Hill, MA, USA.
21 **8:** DNA-Protein Interactions Unit, School of Biochemistry, University of Bristol, Bristol, BS8
22 1TD, UK.
23 **9:** Host Pathogen Interactions Group, School of Biochemistry and Immunology, Trinity
24 College Dublin, Dublin 2, Ireland.
25 **10:** Schools of Microbiology and Medicine, and APC Microbiome Ireland, University College
26 Cork, Cork, Ireland.

27
28 * Contributed equally to this work

29 § Corresponding author (email: ruth.massey@bristol.ac.uk or r.massey@ucc.ie)

30
31 **Keywords:** *Streptococcus pneumoniae*, ICE elements, pneumolysin regulation, ZomB
32 protein.

33

34

35 **Abstract**

36 *Streptococcus pneumoniae* is a major human pathogen that can cause severe invasive
 37 diseases such as pneumonia, septicaemia and meningitis. Young children are at a
 38 particularly high risk, with an estimated half a million deaths worldwide in those under five
 39 attributable to invasive pneumococcal disease each year. The cytolytic toxin pneumolysin
 40 (Ply) is a primary virulence factor for this bacterium, yet despite its key role in pathogenesis,
 41 immune evasion, and transmission, the regulation of Ply production is not well defined.
 42 Using a genome-wide association approach we identified a large number of potential
 43 effectors of Ply activity, including a gene acquired horizontally on the antibiotic resistance
 44 conferring Integrative and Conjugative Element (ICE) ICE*Sp23FST81*. This gene encodes a
 45 novel modular protein, ZomB, which has an N-terminal UvrD-like helicase domain followed
 46 by two Cas4-like domains with potent ATP-dependent nuclease activity. We found the
 47 regulatory effect of ZomB to be specific for the *ply* operon, potentially mediated by its high
 48 affinity for the BOX repeats encoded therein. Using a murine model of pneumococcal
 49 colonisation, we further demonstrate that a ZomB mutant strain colonises both the upper
 50 respiratory tract and lungs at higher levels when compared to the wild type strain. While the
 51 antibiotic resistance conferring aspects of ICE*Sp23FST81* is often credited with contributing
 52 to the success of the *S. pneumoniae* lineages that acquire it, its ability to control the
 53 expression of a major virulence factor implicated in bacterial transmission is also likely to
 54 have played an important role.

55
 56
 57
 58
 59
 60
 61
 62

63

64 **Introduction**

65 For opportunistic pathogens, such as *Streptococcus pneumoniae*, there is a fine balance to
 66 be reached between the ability to colonise the host asymptotically, to transmit between
 67 hosts, and to cause disease symptoms [1-3]. The secretion of cytolytic toxins is often key to
 68 this. *S. pneumoniae*, for example, produces pneumolysin (Ply), a cytolytic pore-forming toxin
 69 that binds to cholesterol in the membranes of host cells, where it inserts into the lipid bilayer
 70 forming a transmembrane pore that lyses the host cell [4-7]. Ply also affects the host
 71 immune system in a complex manner, with evidence for both pro- and anti-inflammatory
 72 activity [8-11]. The data surrounding the role of Ply in nasal colonisation is complex, with
 73 early studies suggesting it contributed positively to the colonisation process [12], but more
 74 recent work showing its expression to inversely correlate with colonisation duration and
 75 directly correlate with shedding of *S. pneumoniae* from the nose for transmission to new
 76 hosts [13-15]. Given the importance of Ply to many aspects of the biology of *S. pneumoniae*
 77 it represents an attractive target for the development of therapeutic intervention [16].

78

79 Despite its importance, what is perhaps surprising about Ply is that so little is known about
 80 its regulation compared to the virulence factors of similar pathogens, such as
 81 *Staphylococcus aureus*. To begin to address this, here we sought to define the genetic basis
 82 of Ply activity by analysing a collection of 165 isolates belonging to the *S. pneumoniae*
 83 PMEN1 lineage [17]. This globally successful clonal group (also known as vaccine serotype
 84 23F, multilocus sequence type 81) is of historical importance having made an important
 85 contribution to the emergence of penicillin non-susceptibility amongst the pneumococci [18].
 86 It has acquired further antibiotic resistance through the acquisition of the Integrative and
 87 Conjugative Element (ICE) ICESp23FST81 [8], which confers resistance to tetracycline,
 88 macrolides and chloramphenicol, features believed to have contributed to the success of this
 89 lineage. As such it represents an important and relevant lineage on which to base this study.

90

91

92 **Materials and Methods**

93 **Bacterial strains and growth conditions.**

94 Clinical isolates used in this study (listed in supp. table 4) had been previously sequenced
95 [17] and all belonged to the PMEN1 clone of which *S. pneumoniae* ATCC 700669 is the
96 reference strain. Strains were grown for 16-24 hours in 5% CO₂ at 37°C, on either brain-
97 heart infusion (BHI), Todd Hewitt supplemented with 0.5% (w/v) yeast extract (THY), blood
98 agar plates containing 5% (v/v) defibrinated horse blood, or in BHI/THY broth without blood.
99

100 **Construction of deletion mutants in *S. pneumoniae*.**

101 Genes were deleted in *S. pneumoniae* using linear PCR products as described previously
102 [19]. In brief, a stitch PCR approach using the primers listed in Table 1 were used to
103 generate a single PCR product consisting of 1kb of DNA to either side of the gene to be
104 deleted, with a gene encoding resistance to erythromycin (*ermAM* - amplified from plasmid
105 pVA838) in the centre. To transform the bacteria with this PCR product, the wild type
106 bacteria were grown overnight in 5ml BHI broth, and 2ml of this culture was used to
107 inoculate a pre-warmed tube of 20ml BHI broth. This was incubated for a further 2 hours,
108 and 0.5ml was added to 9.5ml pre-warmed BHI broth and incubated for 30 minutes. 1ml of
109 this sub-culture was transferred to sterile tubes, 10µl of 10µg/ml competence-stimulating
110 peptide-2 (CSP-2) was added each, and these were incubated for 15 minutes. To 200 µl
111 aliquots of this, either the PCR product or sterile water was added, and the mixture
112 incubated for a further 2 hours. This was then added to molten BHI agar (10ml) containing
113 5% (v/v) defibrinated horse blood, allowed to set in a petri dish and incubated for 2 hours.
114 Plates were then overlaid with a further 10ml molten agar containing 5% (v/v) defibrinated
115 horse blood with erythromycin (2µg/ml) to select for successfully transformed cells. Plates
116 were incubated for up to five days at 37°C, or until colonies appeared within the agar.

117

118 **Cloning of ZomB for complementation**

119 The *zomB* gene was amplified by PCR from ATCC 700669 using KAPA HiFi HotStart
120 ReadyMix (Roche) and primers *zomBFW*: atatgcatgccctcgtaattactaggaaac (SpHI, T_m 67.6
121 °C) and *zomBRV*: atatggatccattttcttatctatagattctaaaatac (BamHI, T_m 63.7) and cloned into
122 the pVA838 plasmid [20] using MAX Efficiency™ DH5α Competent Cells (Invitrogen) to
123 make pVA838-*zomB*. The plasmid was purified and transformed into D39 as described
124 above, using CSP-1 in place of CSP-2.

125

126 **Quantification of Ply activity**

127 Strains were grown overnight in BHI broth, then sub-cultured at a 1:1 ratio into fresh broth
128 and grown for one hour until OD_{600nm} of 0.4-0.7 was reached. These cultures were then
129 serially diluted 4-fold in a 96 well plate containing BSA assay buffer (0.05g bovine serum
130 albumin and 77mg dithiothreitol dissolved in 50ml sterile phosphate buffered saline. To each
131 well, 50µl of triple-washed sheep red blood cells (at a final concentration of 2% diluted in
132 PBS (v/v)) were added and the plates were incubated for one hour in 5% CO₂ at 37°C. The
133 plates were then centrifuged at 2000rpm for 10 minutes at room temperature to separate the
134 intact cells from the soluble lysed material. The supernatants from each well were
135 transferred to a fresh 96-well plate and absorbance values read at 415nm were obtained
136 using a FLUOstar Omega microplate reader.

137

138 **GWAS**

139 The initial Genome-wide associations between single nucleotide polymorphisms (SNP) and
140 bacterial toxicity were determined by means of linear regression. To account for bacterial
141 population structure, we first performed a singular value decomposition (PCA) of the SNP
142 data and then used the first four principal components (PC), which together explained
143 around 45% of the variance, in the regression model

$$144 \quad toxicity \sim \beta_0 + \beta_1 SNP + \beta_2 PC_1 + \beta_3 PC_2 + \beta_4 PC_3 + \beta_5 PC_4.$$

145 Statistical significance of the β_1 term was determined at an uncorrected $\alpha = 0.05$ threshold.

Subsequent GWAS analyses of the data by pyseer and BugWas were performed as previously described [21,22].

Quantification of Ply production

The bacteria were grown overnight in 15ml BHI broth and harvested by centrifugation. Supernatant proteins were precipitated with 20% trichloroacetic acid, washed 3 times in acetone and resuspended in 100 µl of 8M urea. The individual proteins were separated on an SDS-PAGE gels and Western blotting of this conducted using anti-pneumolysin antibody followed by goat anti-mouse IgG HRP as the secondary antibody. The HRP signal was detected using the Metal Enhanced DAB Substrate Kit (ThermoScientific).

Quantification of transcription of the *ply* gene

Bacteria were grown overnight in 5-10ml BHI broth and RNA was extracted using a Zymo Quick-RNA Fungal/Bacterial Miniprep kit following the manufacturer's protocol. Turbo DNase digest kit was used to remove any contaminating DNA. The quality and quantity of the RNA was determined using a Nanodrop and the RNA was reverse transcribed to cDNA using a qScript cDNA synthesis kit (QuantaBio, Beverly, USA), as per the manufacturer's protocol. RNA samples were standardised such that 100ng was added to each cDNA synthesis reaction. qPCR was performed using a Mic qPCR cyclers (Bio Molecular Systems) and reactions were set up using a KAPA Sybr Fast universal master mix (no rox). Three technical repeats were conducted for each cDNA sample and the data analysed using the $2^{-(\Delta Ct \text{ ply} - \Delta Ct \text{ recA})}$ method [23]. The cycle parameters included an initial denaturation at 95°C for 3 min, followed by 35 cycles of 95°C for 10 sec, annealing at 60°C for 20 sec, and elongation at 72°C for 20 sec. A melt curve analysis was performed to check amplified products. The primer pairs used where *recA* was used as the control housekeeping gene:

ply FW: GAAGACCCCAGCAATTCAAG

ply RV: CCTTGAGTTGTTCCATGCTG

174 recA FW: ATCGGAGATAGCCATGTTGG

175 recA RV: ATAGAGGCGCCAAGTTTACG

176

177 **Expression and purification of ZomB.**

178 The *zomB* gene was cloned into the expression plasmid pET15b, and expressed in *E. coli*
179 strain BL21(DE3) with a 6x histidine tag at its N-terminus. The *E. coli* cells were grown at
180 37°C in LB broth containing 100µg/ml ampicillin to an OD_{600nm} of around 0.5, whereupon
181 cells were temperature acclimatised to 18°C and gene expression was induced for 12 hours
182 via the addition of 1mM IPTG. Cells were harvested by centrifugation for 20 minutes at
183 6000rpm and resuspended in buffer containing 50mM Tris pH 7.5, 150mM NaCl, 10%
184 sucrose and 0.1mM PMSF. Cells were lysed by sonication in buffer containing 1mM TCEP,
185 500mM NaCl, 20mM imidazole and a protease inhibitor cocktail, and cell debris was
186 removed by centrifugation for 30 minutes at 21,500rpm. Cell lysate was loaded onto a 5ml
187 HisTrap Nickel binding column which had been equilibrated in HisB buffer (20mM Tris
188 pH7.5, 500mM NaCl, 1mM TCEP, 5% glycerol) plus 20mM imidazole. Proteins possessing
189 His-tags were eluted with a gradient from 20mM to 500mM imidazole over 32 minutes with a
190 flow rate of 3ml/min. Protein elution was monitored by measuring absorbance at 280nm.
191 Fractions containing the most protein were pooled and applied to a HiTrap Heparin affinity
192 column equilibrated with HepQ/B buffer (20mM Tris pH7.5, 1mM TCEP) plus 100mM NaCl.
193 Heparin-binding proteins were eluted with a gradient from 100mM to 1M NaCl over 30
194 minutes, monitored by absorbance at 280nm. Two millilitre fractions containing the highest
195 protein concentrations were pooled and applied to a MonoQ anion exchange
196 chromatography column equilibrated with HepQ/B buffer plus 100mM NaCl. Proteins were
197 eluted with a gradient from 100mM to 1M NaCl over 30 minutes, with protein absorbance
198 monitored at 280nm, and 0.3ml fractions were collected. Fractions containing the highest
199 concentrations of eluted protein were pooled and stored in HepQ/B buffer plus 330nM NaCl,
200 corresponding to the salt concentration at which the protein was eluted from the column.

201 Nanodrop OD₂₈₀ and the ZomB protein's predicted extinction coefficient (118390mol/L/cm)
202 were used to determine that ZomB had been purified to a concentration of 7.0µM.

203

204 **Biochemical characterisation of ZomB activity**

205 ATPase activity was measured by coupling the hydrolysis of ATP to the oxidation of NADH
206 which gives a change in absorbance at 340nm. Reactions were performed in a buffer
207 containing 20 mM Tris-Cl pH 8.0, 50 mM NaCl, 2 mM DTT, 1 mM MgCl₂, 50 U/mL lactate
208 dehydrogenase, 50 U/mL pyruvate dehydrogenase, 1 mM PEP and 100 µg/mL NADH.
209 Rates of ATP hydrolysis were measured over 1 min at 25°C and the ssDNA substrate used
210 was Poly(dT). For calculation of K_{DNA} (defined as the concentration of DNA at which ATP
211 hydrolysis is half-maximal), the ATP concentration was fixed at 2 mM. The Michaelis-Menten
212 plot was performed at saturating DNA concentration which is defined as 10x the K_{DNA} value.
213 The concentration of ZomB was 50 nM in these assays unless indicated otherwise.

214

215 **Electrophoretic mobility shift assays**

216 The intergenic region between *ply* and the neighbouring gene SPN23F19460, containing
217 BOX repeat regions was amplified (using the following primers; BoxF:
218 GAGAGGAGAATGCTTGCGAC and BoxR:
219 TAGGAATCTCCTTTTTTCACATTTTAATCTTTC). A region of the *ply* gene of equivalent
220 size was also amplified (using plyF: ATGGCAAATAAAGCAGTAAATGACTTTATAC and
221 plyR: GCCCCCTAAAATAACCGCCTTC). The purified ZomB protein was added in a range
222 of concentrations (5µM, 2.5µM, 1.25µM, 0.625µM, 0.3125µM and 0.15625µM) to 10nM
223 of the PCR products in a buffer containing 20mM Tris (pH 8), 200mM sodium chloride, 1mM
224 Tris(2-carboxyethyl) phosphine (TCEP) and 10% glycerol. Samples were then run on a 1.5%
225 agarose gel in 1X TAE buffer for 110 minutes at 90V. Following this, the gel was stained in
226 TAE containing 1X SYBR Safe DNA gel stain for 30 minutes, and bands were visualised
227 using a Typhoon FLA 9500.

228

229 RNA sequencing

230 Three independent 20 ml cultures of *S. pneumoniae* ATCC 700669 wild type
 231 and $\Delta zomB$ mutant were grown overnight in Todd Hewitt broth supplemented with 0.5%
 232 yeast extract, from which total RNA was extracted and DNase treated as described above.
 233 RNA was stored at -70°C until transportation on ice for sequencing at the University of
 234 Bristol Genomics Facility. RNA integrity was determined by electrophoresis using
 235 TapeStation (Agilent) RNA Screentape Assay and samples with scores of > 7 were
 236 considered suitable for library preparation and sequencing.
 237
 238 One hundred nanograms of total RNA was taken into the Illumina TruSeq Stranded Total
 239 RNA with Illumina Ribo-Zero Plus rRNA Depletion kits according to the manufacturer's
 240 instructions. Briefly, the protocol involved enzymatic depletion of ribosomal RNA and clean-
 241 up of the remaining RNA using magnetic beads. The RNA was fragmented and denatured,
 242 and first and second strand cDNA was synthesised, then total cDNA purified using magnetic
 243 beads. The 3' ends were adenylated to prevent blunt end ligation, and indexing adapters
 244 were ligated to the ends of the double stranded cDNA fragments. Magnetic beads
 245 (Agencourt AMPure XP beads, Beckman Coulter) were then used to clean up the cDNA
 246 libraries before amplification of DNA fragments, selecting for adapter molecules. A second
 247 clean up with magnetic beads was performed and the libraries were quantified using the
 248 ThermoFisher High Sensitivity dsDNA Qubit assay and validated using the TapeStation
 249 (Agilent) with the DNA100 screentape assay. The cDNA libraries were normalised to 4nM
 250 and pooled for sequencing on the Illumina NextSeq500 instrument using a High Output
 251 Version 2.5 sequencing kit. The indices for each sample are detailed in Table 2. The depth
 252 of sequencing covered 2 x 75bp paired end reads, with a minimum of 30 million reads per
 253 sample. Sequence information was output into FastQ file format for subsequent downstream
 254 analysis.
 255

256 Bioinformatic analysis of RNA-sequencing data

FASTQ output files from the Illumina sequencing platform (four files for each forward and reverse read (one for each lane used in sequencing)) were concatenated into a single file for each forward and reverse for each sample. The FASTQ files were checked for quality using FASTQC (version 0.11.9, Brabraham Bioinformatics, UK), ensuring consistency and high-quality scores, particularly within 'per base sequence quality' and 'per sequence quality score' tabs. These files were then taken through a bioinformatics pipeline (via terminal on an Apple MacBook pro running macOS Catalina (version 10.15.7)) detailed below.

An index for the *S. pneumoniae* reference genome (GenBank accession GCA_000026665.1) was created using Bowtie 2 [24] (version 2.4.1), and FASTQ files were aligned to this also using Bowtie 2. Overall alignment rate for the samples was between 87.54% to 97.28%. The annotated genome was then used to create a sequence alignment map (SAM) using SAMtools [25] (version 1.11). Here, a quality control step involved viewing the header of the files to check for quality scores and correct file format. The SAM files were sorted and converted to binary alignment map (BAM) files using SAMtools. The annotated genome was then used as a reference for counting the sorted BAM file reads using Subread featureCounts [26] (version 2.0.1) including options for paired-end reads.

The featureCounts output file was imported into RStudio (Version 1.2.5033) for differential expression analysis using DESeq2 [27] (version 1.26.0). The RStudio source code is available upon request. The aligned BAM files and reference can be obtained at the NCBI Sequence Read Archive (SRA) under accession PRJNA706751.

Mouse intranasal challenge

8–10-week-old female C57/Black6 mice were inoculated intra-nasally with 1×10^6 CFU of WT, or an isogenic ZomB deficient strain under isoflurane anaesthetic. Mice were culled at specific time points post inoculation. The upper respiratory tract was lavaged by the insertion of a 20-gauge IV catheter into the trachea with 1ml of sterile PBS washed through and

collected at the nose. Lungs were removed and homogenised in 1ml of sterile PBS. Lung homogenate and nasal lavage, where plated on BHI agar with 5% (v/v) defibrinated horse blood and 2.5µg/ml tetracycline for enumeration of CFU.

Ethics statement

C57/Bl6 mice were bred in-house in Trinity College Dublin. All mice were housed under specific pathogen-free conditions at the Trinity College Dublin Comparative Medicines unit. All mice were used at 8–10 weeks. All animal experiments were conducted in accordance with the recommendations and guidelines of the health product regulatory authority (HPRA), the competent authority in Ireland and in accordance with protocols approved by Trinity College Dublin Animal Research Ethics Committee.

Results

To examine what variability exists in the production of Ply across a collection of closely related *S. pneumococcal* clinical isolates we first constructed a *ply* mutant in the pneumococcal PMEN1 isolate ATCC 700669 [8] by replacing the *ply* gene with an erythromycin resistance cassette. Using this wild type and mutant strain as positive and negative controls we quantified the Ply activity (lysis of sheep red blood cells (RBCs)) of 165 PMEN1 clinical isolates in triplicate, demonstrating that it varied significantly across this collection of closely related isolates (Fig. 1a). As the genomes of each of these isolates have been sequenced [17], we applied three complementary genome-wide association (GWAS) approaches to identify loci associated with Ply activity. In addition to a linear regression approach using the SNP (single nucleotide polymorphism) data, we also applied two methods that make use of kmer (lengths of nucleotide sequences) data: *BugWAS* [21] and *pyseer* [22]. The results from each of these methods are presented in supplementary tables 1-3. A Manhattan plot in Fig. 1b shows the significantly associated genetic loci determined through the SNP-based method, highlighting those loci where two or all three GWAS methods agreed. (Note, the *P* values are not comparable between the three methods, so this

graph is provided as an illustration of the genomic location of the commonly associated loci). There were two notable observations from these analyses. The first was that five loci were associated with Ply activity across all three methods, with the *pbpX* gene, which encodes the Penicillin Binding Protein 2x, being the most significant. This was followed in order of significance by the intergenic region between a gene with the locus tag SPN23F05820 and *bgaA*, a gene with the locus tag SPN23F00840, the intergenic region between a gene with the locus tag SPN23F19120 and *msmG*, and the intergenic region between a gene with the locus tag SPN23F14800 and *greA*. The second notable observation was that 48 individual genes or intergenic regions on the Integrative and Conjugative Element (ICE) ICESp23FST81 were associated with Ply activity.

Fitness trade-offs between antibiotic resistance and virulence in bacteria are well established [28-31], and for both clinical isolates and isogenic mutants the acquisition of penicillin resistance has been shown to decrease the virulence of *S. pneumoniae* in murine models of infection [32,33]. Given the association of the *pbpX* gene and Ply activity, we hypothesised that a similar trade-off may be occurring here, such that the polymorphisms in the *pbpX* gene may be increasing the levels of resistance to penicillin, which may consequently reduce the levels of Ply being produced, or vice versa. Although bacterial GWAS results are typically validated through mutation of the associated locus, the contribution of the protein encoded by *pbpX* to the biosynthesis of the peptidoglycan layers in the bacterial cell wall is such that it is essential and cannot be inactivated. Instead, we tested our hypothesis by examining the levels of resistance to penicillin (minimum inhibitory concentrations, MICs) for the isolates, but found no significant correlation between the MICs and Ply activity (Pearson product-moment correlation $r^2 = 0.076$, $P = 0.36$). An alternative hypothesis is that the polymorphisms in the *pbpX* gene affects the stem peptide composition of peptidoglycan, as this has been shown to inhibit the release of Ply from the bacterial cells [34]. Further work to test this hypothesis is currently underway.

341 The high number of associated loci on ICESp23FST81 is particularly intriguing. This mobile
 342 genetic element (MGE), which can be found both integrated and in plasmid form (illustrated
 343 in Fig. 2a), is believed to be critical to the success of this lineage of *S. pneumoniae* due to
 344 the antibiotic resistance capabilities it brings to the bacteria [8]. Given its ability to move
 345 horizontally as a single contiguous unit between bacteria, it is likely that of the associated
 346 loci only one is an effector of Ply activity, whilst the others are associated through their
 347 physical linkage to this. A survey of the putative activity of all 48 associated loci revealed that
 348 the majority of these are genes typical to such elements, involved in antibiotic resistance and
 349 the mechanics of its movement. An interesting exception is a gene with the locus tag
 350 SPN23F12470. This locus has been annotated as encoding a UvrD-like helicase, a family of
 351 proteins typically associated with core house-keeping activities for bacteria. Further *in silico*
 352 analysis of the encoded protein, that we have named ZomB, suggests that it is a multi-
 353 domain protein with a putative DNA binding helicase domain, followed by two Cas4-like
 354 nuclease domains which are predicted to harbour 4Fe-4S clusters [35] (Fig. 2b). With
 355 several known examples of Cas-like proteins regulating bacterial virulence [36-38], we
 356 hypothesised that it is this gene on ICESp23FST81 that is the effector of Ply activity.

357

358 To establish the role of ZomB in Ply activity we replaced the *zomB* gene with an
 359 erythromycin resistance cassette in *S. pneumoniae* strain ATCC 700669. While no
 360 differences in growth between the wild type and mutant strains was observed, the RBC lytic
 361 activity of the *zomB* mutant was significantly impaired relative to the wild type strain (Fig. 2c).
 362 Using anti-Ply antibodies in a Western blot to understand the mechanism by which ZomB
 363 affects Ply activity, we found that this reduction in lytic activity was due to a decrease in the
 364 amount of Ply protein being released into the bacterial supernatant (Fig. 2d). We also
 365 quantified the relative transcription of the *ply* gene by qRT-PCR and found that the reduced
 366 abundance of Ply was due to a significant decrease (19-fold) in *ply* transcription when the
 367 *zomB* gene was inactivated (Fig. 2e). Despite numerous attempts to complement this
 368 mutation we were unable re-transform the *zomB* mutant with a plasmid containing the *zomB*

gene, or the empty pVA838 plasmid. So instead, we introduced it into a more genetically amenable *S. pneumoniae* strain, D39, which does not contain ICESp23FST81 or the *zomB* gene. The introduction of the *zomB* expressing plasmid to this strain did not increase the ability of the strain to lyse RBCs, or increase its production of Ply (Fig. 2c and 2d). However, the introduction of the *zomB* plasmid significantly increased the transcription of the *ply* gene in D39, verifying the positive effect ZomB has on *ply* expression (Fig. 2e). It is possible that the increase in *ply* transcription did not affect the level of Ply production in this strain due to it being already quite a high Ply producer where it's protein translational machinery or it's secretory mechanism may already working at a maximal level.

To characterise the biochemical activities of the ZomB protein, we expressed and purified recombinant ZomB with an N-terminal 6x histidine tag (Fig. 3a). Using a coupled-assay, we found that ZomB hydrolyses ATP with Michaelis-Menten kinetics and displays a turnover number of approximately 20 s^{-1} and a K_m value of $90\text{ }\mu\text{M}$ ATP (Fig. 3b). These experiments were performed in the presence of saturating quantities of ssDNA, which was shown to strongly stimulate ATP hydrolysis with an apparent dissociation constant of approximately $1\text{ }\mu\text{M}$ (ntds) (Fig. 3c). This behaviour is typical of the UvrD-like DNA helicases of which ZomB is a member [39]. To examine the putative nuclease activity, ZomB protein (50nM) was incubated with duplex DNA with and without ATP and Mg^{2+} . Degradation of the DNA by ZomB was monitored by gel electrophoresis, which showed that the protein possesses a potent ATP-dependent nuclease activity (Fig. 3d).

Given the *in vitro* DNA binding and nuclease activity of ZomB, and its role in the transcription of the *ply* gene, we sought to determine the scale of its regulatory activity. To examine this, we compared the level of transcription of all *S. pneumoniae* strain ATCC 700669 coding regions between the wild type and *zomB* mutant using RNA-seq. Under the growth conditions used (i.e. overnight cultures grown in Todd Hewitt broth supplemented with 0.5% yeast extract), we used a >2-fold difference in expression and a P value of <0.05 following

Benjamini-Hochberg adjustment as our significance threshold. We found the transcription of nine genes to be affected by the loss of the *zomB* gene, with those genes encoded within the *ply* locus being the most significantly affected (Table 3, Fig. 4).

The *ply* gene is transcribed as part of an operon with four other genes that encode a transcriptional regulator (YebC) and proteins implicated in the movement of Ply from the cytosol to the bacterial cell wall (SPN23F19480-19500) (Fig. 5a) [40, 41]. The operon also contains a BOX repeat region immediately downstream of the *ply* gene. Due to their internal repeating sequences, BOX regions can form stable secondary structures, and their presence has been associated with altered transcription of neighbouring genes [42,43]. The molecular details of how their presence affects gene transcription has not yet been determined but is likely due to these secondary structures where they can either enhance or interfere with transcription processes depending on their relative positioning [43]. As ZomB appears to be a positive effector of *ply* transcription, and given its likely DNA binding capability, we hypothesised that it may directly interact with the *ply* locus, perhaps via its BOX region. To test this we amplified two regions of DNA from within the *ply* locus, one containing the BOX element from within the *ply* operon, as well as an equivalently-sized region of DNA within the *ply* coding region, and performed electrophoretic mobility shift assays (EMSAs) with increasing concentrations of ZomB protein. As visualised in Fig. 5b & 5c, the ZomB protein caused a shift in size of both regions of DNA with a higher level of affinity for the BOX containing DNA evidenced by the shift occurring at lower concentrations of protein and with a clearer (less fuzzy) shift in the DNA. While it is tempting to speculate from this that the effect of ZomB on the transcription of the *ply* locus might be mediated via the BOX region, that the transcription of none of the genes neighbouring the other 136 BOX regions scattered across the *S. pneumoniae* genome were affected by the loss of the *zomB* gene does not support this (Table 1 Fig. 4). But what is clear from this analysis is that the ZomB protein can bind to at least two regions within the *ply* locus with a high affinity, and this is likely to be the means by which it elicits its effect on the transcription of these genes.

425

426 The ability of pathogens to alter expression of key virulence factors to counteract host
 427 immune responses is a critical strategy of disease tolerance employed by obligate
 428 symbionts, such as *S. pneumoniae*, to facilitate persistence within its host [44,45]. In the
 429 absence of Ply a reduced local pro-inflammatory response [13,46] coupled with the potential
 430 for a more intracellular lifestyle [41,47] has been shown to promote persistence both in the
 431 nasopharynx and in the lungs. With Ply expression inversely correlated with colonisation, we
 432 sought to determine how ZomB, a regulator of *ply* transcription, would affect *S. pneumoniae*
 433 colonisation in a murine model. Mice were inoculated intra-nasally with a sub-lethal dose of
 434 either the wild type or ZomB mutant and nasopharyngeal bacterial burden monitored over 7
 435 days (Fig. 6). The ZomB mutant demonstrated increased persistence within the nasopharynx
 436 compared to the wild type strain with increased numbers of ZomB mutant bacteria recovered
 437 from the upper respiratory tract at days 3 and 7 post inoculation (Fig 6a). Consistent with
 438 this, significantly increased levels of pneumococci were also recovered from the lungs of the
 439 ZomB mutant challenged animals compared to animals challenged with the wild-type strains
 440 on day 7 post colonisation (Fig 6b).

441

442 Discussion

443 Through the application of a functional genomics approach to a large collection of
 444 sequenced *S. pneumoniae* isolates, we have identified >100 novel putative effectors of Ply
 445 activity (supp. tables 1-3). Of these associated loci we have determined the molecular detail
 446 of the interaction between the ZomB protein encoded on ICESp23FST81 and Ply activity,
 447 where ZomB acts as a positive transcriptional regulator of the *ply* operon. We demonstrate
 448 that ZomB has ATP dependent nuclease activity and that it can bind with high affinity to
 449 multiple regions within the *ply* locus. Further work is required? to understand how the binding
 450 of ZomB to this locus affect its transcription, but we hypothesis its role is in the unravelling of
 451 secondary structures that would otherwise limit pneumolysin gene transcription.

452

Amongst the other loci identified by all three GWAS approaches as associated with Ply production were *bgaA* and *msmG*, two genes involved in carbohydrate utilisation. BgaA is a surface expressed b-galactosidase known to play a role in pneumococcal growth, resistance to opsonophagocytic killing, and adherence [48], whereas MsmG is part of the multiple sugar metabolism system [49]. A close relationship between metabolism and virulence is well established for other bacterial pathogens [50-52], and this has been recently established for the pneumococci where a clear link between capsule production and metabolism has been established. This work suggests that the effect of pneumococcal metabolism on its virulence may extend beyond capsule production and include an effect of Ply production, which is currently under investigation.

In this work we have identified and characterised a gene encoded on an MGE with specific and targeted activity for an operon that is critical to several aspects of the biology of *S. pneumoniae*. The PMEN1 lineage is believed to have emerged from a relatively unremarkable background lineage (CC66) to become a globally successful pathogenic lineage, and this is at least partially attributed to the acquisition of ICESp23FST81 [8,17,18]. This MGE, which is present across the whole PMEN1 lineage, confers resistance to tetracycline, macrolides and chloramphenicol and thus provides a clear benefit upon exposure to these antibiotics. However, for many bacterial species antibiotic resistance often incurs a fitness cost in the absence of the antibiotic, which can be offset, for example, by reducing the energetically costly production of toxins [28,29]. Here, in stark contrast, we observe the simultaneous acquisition of increased resistance with increased toxin production. We believe this work has uncovered an intriguing form of interdependency between a host bacterium and an MGE, where increased Ply expression due to the contribution this makes to transmission, has potentially converted a strain from being a stable coloniser to an efficient transmitter. The long-term benefit the contribution ZomB makes to this conversion may override the short-term increased energetic costs, potentially resulting in the evolution of this globally successful pneumococcal lineage.

481

482 **Authors Statements**

483 **Authors contributions:** EJS, DJM & DB develop methodology, performed experiment,
484 analysed data and contributed to writing the manuscript. SD & TB provided support and
485 supervision. MR analysed data and contributed to writing the manuscript. JAL, NJC, DJW,
486 SJE & RD analysed data. SB & NJC provided resources. AN, HJ, TvO and DT provided
487 guidance, expertise and resources. OJW and MSD performed experiments and provided
488 advice on helicase proteins. SC and RMM designed performed and analysed the data from
489 the animal experiments, and contributed to writing the manuscript. RCM conceptualised the
490 project, developed the methodology, secured the funding, provided supervisory oversight
491 and wrote the manuscript.

492 **Conflicts of interest:** the authors declare that there are no conflicts of interest.

493 **Funding Information:** E.J.S. was a BBSRC SWBio DTP funded PhD student. R.C.M. and
494 R.M.M. are Wellcome Trust funded Investigators (Grant reference number: 212258/Z/18/Z).
495 D.J.W. is a Sir Henry Dale Fellow, jointly funded by the Wellcome Trust and the Royal
496 Society (Grant 101237/Z/13/B) and is supported by a Big Data Institute Robertson
497 Fellowship

498 **Acknowledgements:** We would also like to thank Prof. Tim Mitchell for helpful discussions
499 during the preparation of this manuscript.

500

501 **REFERENCES**

- 502 1. **Deng, X. et al.** Whole-genome sequencing reveals the origin and rapid evolution of an
503 emerging outbreak strain of *Streptococcus pneumoniae* 12F. *Clin Infect Dis*
504 2016;62:1126-1132.
- 505 2. **Ioachimescu, O.C., Ioachimescu, A.G. & Iannini, P.B.** Severity scoring in community
506 acquired pneumonia caused by *Streptococcus pneumoniae*: a 5-year experience. *Int J*
507 *Antimicrob Agents* 2004;24:485-490.
- 508 3. **O'Brien, K.L. et al.** Burden of disease caused by *Streptococcus pneumoniae* in children
509 younger than 5 years: global estimates. *Lancet* 2009;374:893-902.
- 510 4. **Canvin, J.R. et al.** The role of pneumolysin and autolysin in the pathology of pneumonia
511 and septicaemia in mice infected with a type 2 pneumococcus. *J Infect Dis*
512 1995;172:119-123.
- 513 5. **Hirst, R.A. et al.** The role of pneumolysin in pneumococcal pneumonia and meningitis.
514 *Clin Exp Immunol* 2004;138:195-201.

- 515 6. **Hirst, R.A. et al.** *Streptococcus pneumoniae* deficient in pneumolysin or autolysin has
516 reduced virulence in meningitis. *J of Infect Dis* 2008;197:744-751.
- 517 7. **Mitchell, A.M. & Mitchell, T.J.** *Streptococcus pneumoniae*: virulence factors and
518 variation. *Clin Microbiol Infect Dis* 2010;16:411-418.
- 519 8. **Croucher, N.J. et al.** Role of Conjugative Elements in the Evolution of the Multidrug-
520 Resistant Pandemic Clone *Streptococcus pneumoniae* Spain23F ST81. *J Bacteriol*
521 2009;191:1480-9.
- 522 9. **Mitchell, T.J. et al.** Complement activation and antibody binding by pneumolysin via a
523 region of the toxin homologous to a human acute-phase protein. *Mol Microbiol* 1991;5:
524 1883-8.
- 525 10. **Paton, J.C., Rowan-Kelly, B. & Ferrante, A.** Activation of human complement by the
526 pneumococcal toxin pneumolysin. *Infect Immun* 1984;43:1085-7.
- 527 11. **Subramanian, K. et al.** Pneumolysin binds to the mannose receptor C type 1 (MRC-1)
528 leading to anti-inflammatory responses and enhanced pneumococcal survival. *Nat*
529 *Microbiol* 2019;4:62-70.
- 530 12. **Kadlioglu, A., et al.** Upper and lower respiratory tract infection by *Streptococcus*
531 *pneumoniae* is affected by pneumolysin deficiency and differences in capsule type.
532 *Infect Immun* 2002;70:2886-90.
- 533 13. **van Rossum, A.M., Lysenko, E.S. & Weiser, J.N.** Host and bacterial factors
534 contributing to the clearance of colonization by *Streptococcus pneumoniae* in a murine
535 model. *Infect Immun* 2005;73:7718–26.
- 536 14. **Zafar, M.A., Wang, Y., Hamaguchi, S. & Weiser, J.N.** Host-to-Host Transmission of
537 *Streptococcus pneumoniae* Is Driven by Its Inflammatory Toxin, Pneumolysin. *Cell Host*
538 *Microbe* 2017; 21:73-83.
- 539 15. **Riegler, A.N. Brissac, T., Gonzalez-Juarbe, N. & Orihuela C.J.** Necroptotic Cell
540 Death Promotes Adaptive Immunity Against Colonizing Pneumococci. *Front Immunol*
541 2019;10:615.
- 542 16. **Anderson R, & Feldman C.** Pneumolysin as a potential therapeutic target in severe
543 pneumococcal disease. *J Infect* 2017;74:527-544.
- 544 17. **Croucher, N.J. et al.** Rapid pneumococcal evolution in response to clinical
545 interventions. *Science* 2011;331:430-4.
- 546 18. **Wyres, K.L. et al.** The multidrug-resistant PMEN1 pneumococcus is a paradigm for
547 genetic success. *Genome Biology* 2012;13:R103.
- 548 19. **Chen, L., Ge, X. & Xu, P.** Identifying essential *Streptococcus sanguinis* genes using
549 genome-wide deletion mutation. *Methods Mol. Biol* 2015;1279:15-23.
- 550 20. **Macrina, F.L., Tobian, J.A., Jones, K.R., Evans, R.P. & Clewell D.B.** A cloning vector
551 able to replicate in *Escherichia coli* and *Streptococcus sanguis*. *Gene* 1982;193:345-53.
- 552 21. **Earle, S.G. et al.** Identifying lineage effects when controlling for population structure
553 improves power in bacterial association studies. *Nat. Microbiol* 2016;1:16041.
- 554 22. **Lees, J.A. et al.** pyseer: a comprehensive tool for microbial pangenome-wide
555 association studies. *Bioinformatics* 2018;34:4310-2.
- 556 23. **Livak, K.J. & Schmittgen, T.D.** Analysis of relative gene expression data using real
557 time quantitative PCR and the 2(-Delta Delta C(T)). *Methods* 2001;25:402-8.
- 558 24. **Langmead, B. & Salzberg, S.L.** Fast gapped-read alignment with Bowtie 2. *Nat.*
559 *Methods* 2012;9:357-359.
- 560 25. **Heng, L. et al.** 1000 Genome Project Data Processing Subgroup, The Sequence
561 Alignment/Map format and SAMtools. *Bioinformatics* 2009;25:2078-9.
- 562 26. **Liao, Y., Smyth, G.K. & Shi W.** FeatureCounts: an efficient general purpose program
563 for assigning sequence reads to genomic features. *Bioinformatics* 2014;30:923–930.
- 564 27. **Love, M.I., Huber, W. & Anders, S.** Moderated estimation of fold change and dispersion
565 for RNA-seq data with DESeq2. *Genome Biol* 2014;5:550.
- 566 28. **Rudkin, J.K. et al.** Methicillin resistance reduces the virulence of healthcare-associated
567 methicillin-resistant *Staphylococcus aureus* by interfering with the *agr* quorum sensing
568 system. *J Infect Dis* 2012;205:798–806.

- 569 29. **Collins, J. et al.** Offsetting virulence and antibiotic resistance costs by MRSA. *ISME J*
570 2010;4:577–84.
- 571 30. **Hraiech, S. et al.** Impaired virulence and fitness of a colistin-resistant clinical isolate of
572 *Acinetobacter baumannii* in a rat model of pneumonia. *Antimicrob. Agents Chemother*
573 2013;57:5120–1.
- 574 31. **Linares, J.F., et al.** Overexpression of the multidrug efflux pumps MexCD-OprJ and
575 MexEF-OprN is associated with a reduction of type III secretion in *Pseudomonas*
576 *aeruginosa*. *J. Bacteriol* 2005;187:1384–91.
- 577 32. **Azoulay-Dupuis, E. et al.** Relationship between Capsular Type, Penicillin
578 Susceptibility, and Virulence of Human *Streptococcus pneumoniae* Isolates in Mice.
579 *Antimicrob. Agents Chemother* 2000;44:1575–7.
- 580 33. **Rieux, V., Carbon, C. & Azoulay-Dupuis, E.** Complex relationship Between Acquisition
581 of Beta-Lactam Resistance and Loss of Virulence in *Streptococcus Pneumoniae*. *J*
582 *Infect Dis* 2001;184:66-72.
- 583 34. **Greene, N.G., Narciso, A.R., Filipe, S.R. & Camilli, A.** Peptidoglycan Branched Stem
584 Peptides Contribute to Streptococcus pneumoniae Virulence by Inhibiting Pneumolysin
585 Release. *PLoS Pathog* 2015;11:e1004996.
- 586 35. **Zhang, J., Kasciukovic, T. & White, M.G.** The CRISPR Associated Protein Cas4 Is a 5'
587 to 3' DNA Exonuclease with an Iron-Sulfur Cluster. *PLoS One* 2012;7:e47232.
- 588 36. **Sampson, T.R. et al.** A CRISPR/Cas system mediates bacterial innate immune evasion
589 and virulence. *Nature* 2013;497:254-7.
- 590 37. **Heidrich, N. et al.** The CRISPR/Cas system in *Neisseria meningitidis* affects bacterial
591 adhesion to human nasopharyngeal epithelial cells. *RNA Biol* 2019;16:390-396.
- 592 38. **Ma, K. et al.** cas9 Enhances Bacterial Virulence by Repressing the regR Transcriptional
593 Regulator in *Streptococcus agalactiae*. *Infect Immun* 2018;86:e00552-17.
- 594 39. **Gilhooly, N.S., Gwynn, E.J. & Dillingham, M.S.** Superfamily 1 Helicases. *Front Biosci*
595 2013;5:206-16.
- 596 40. **Fernebro, J. et al.** The influence of in vitro fitness defects on pneumococcal ability to
597 colonize and to cause invasive disease. *BMC Microbiol* 2008;8:65.
- 598 41. **Kimaro Mlacha, S.Z., et al.** Phenotypic, genomic, and transcriptional characterization of
599 *Streptococcus pneumoniae* interacting with human pharyngeal cells. *BMC Genomics*
600 2013;14:383.
- 601 42. **Croucher, N.J., Vernikos, G.S., Parkhill, J. & Bentley, S.D.** Identification, variation and
602 transcription of pneumococcal repeat sequences. *BMC Genomics* 2011;12:120.
- 603 43. **Knutsen, E. et al.** BOX Elements Modulate Gene Expression in *Streptococcus*
604 *Pneumoniae*: Impact on the Fine-Tuning of Competence Development. *J Bacteriol*
605 2006;188:8307-12.
- 606 44. **McCarville, J.L. & Ayres, J.S.** Disease tolerance: concept and mechanisms. *Current*
607 *opinion in immunology* 2018;50:88–93.
- 608 45. **Neill, D.R. et al.** Density and duration of pneumococcal carriage is maintained by
609 transforming growth factor β 1 and T regulatory cells. *Am J Respir Crit Care Med*
610 2014;89:1250-9.
- 611 46. **Wolf, A.I. et al.** Pneumolysin Expression by Streptococcus pneumoniae Protects
612 Colonized Mice from Influenza Virus-induced Disease. *Virology* 2014;0:254–265.
- 613 47. **Inomataa, M. et al.** Macrophage LC3-associated phagocytosis is an immune defense
614 against Streptococcus pneumoniae that diminishes with host aging. *PNAS*
615 2020;117:33561–33569 .
- 616 48. **Singh AK., et al.** Unravelling the multiple functions of the architecturally intricate
617 Streptococcus pneumoniae beta-galactosidase, BgaA. *PLoS Pathog* 2014;0:e1004364.
- 618 49. **Russell RR., et al.** A binding protein-dependent transport system in Streptococcus
619 mutans responsible for multiple sugar metabolism. *J Biol Chem* 1992;267:4631-7.
- 620 50. **Stevens E., Laabei M, Gardner S, Sommerville GA, Massey RC.** Cytolytic toxin
621 production by Staphylococcus aureus is dependent upon the activity of the protoheme
622 IX farnesyltransferase. *Sci Rep* 2017;7:13744.

- 623 51. **Bouillaut L, Dubois T, Sonenshein AL, Dupuy B.** Integration of metabolism and
624 virulence in *Clostridium difficile*. *Res Microbiol* 2015;166:375-83.
- 625 52. **Le Bouguénec C, Schouler C.** Sugar metabolism, an additional virulence factor in
626 enterobacteria. *Int J Med Microbiol* 2011;301:1-6.

627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643

FIGURES





Fig. 1: Genome wide association study (GWAS) to identify novel effectors of pneumolysin (Ply) production by *S. pneumoniae*. **(a)** Pneumolysin activity of 165 *S. pneumoniae* of the PMEN1 lineage, as measured by cell lysis. A wild type (WT) and isogenic pneumolysin mutant (Δ ply) have been included as controls. **(b)** Manhattan plot of the SNP-based GWAS. The horizontal blue dotted line indicates the threshold for significance (not corrected for multiple tests). SNPs in loci identified by two or all three GWAS methods are indicated in blue and orange respectively. The black arrows indicate the regions of interest; 1: SPN23F00840, 2: *pbpX*, 3: intergenic between SPN23F05820 and *bgaA*, 4: ICESp23FST81, 5: intergenic between SPN23F14800 and *greA*, and 6: intergenic between SPN23F19120 and *msmG*.



657

Fig. 2: Inactivation of the *zomB* gene on the ICESp23FST81 affects pneumolysin production. **(a)** Cartoon illustration of ICESp23FST81 in both its linear chromosomally integrated form and circularised plasmid form. Some genes of interest have been included: SPN23F12410, SPN23F13170 and *rplL* because these flank the element in its linear form and come into close association when in the plasmid form. Genes encoding the antibiotic resistance genes for chloramphenicol and tetracycline are also indicated. **(b)** Schematic of the ZomB protein with its helicase and two Cas4-like nuclease domains indicated. **(c)** The lytic activity of the *zomB* mutant is comparable to that of the *ply* mutant as determined by a sheep RBC lysis assay in the ATCC 700669 strain. In the D39 strain the introduction of the

667 *zomB* gene on the pVA838 plasmid did not affect the RBC lytic activity of the bacteria. (d)
668 The presence of Ply in the extracellular medium is reduced in the *zomB* mutant in the ATCC
669 700669 strain, determined using anti-Ply antibodies in a Western blot on concentrated
670 bacterial supernatant. In the D39 strain the introduction of the *zomB* gene on the pVA838
671 plasmid did not affect the level of Ply production. (e) The inactivation of *zomB* in the ATCC
672 700669 strain reduces the transcription of the *ply* gene, and the introduction of the *zomB*
673 gene into the D39 strain increase *ply* transcription. The transcription of *ply* was determined
674 by qRT-PCR, where the data was made relative to the expression of the housekeeping gene
675 *recA* in each sample and normalised to the level of expression on the *ply* gene in the wild
676 type strain. The box plots represent the median and interquartile ranges; individual data
677 points are indicated by open circles.

678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712




Fig. 3: The ZomB protein has ATP dependent nuclease activity. (a) An SDS-PAGE gel showing the purified his tagged ZomB protein. (b) Steady-state ATPase activity of ZomB (50 nM) was measured at saturating ssDNA concentration to determine the Michaelis-Menten parameters. (c) Steady-state ATPase activity of ZomB is strongly stimulated by ssDNA with an apparent dissociation constant of approximately 1 μM ntds. (d) Nuclease assays were performed with linear DNA demonstrating that it was degraded by the ZomB protein in the presence of both ATP and divalent cations.




Fig. 4: ZomB is a positive regulator of the *ply* operon. The transcription of coding regions across the wild type *S. pneumoniae* and ZomB mutant were compared by RNAseq. Only nine genes were significantly affected, and of those the most affected were *zomB* and the five genes encoded on the *ply* operon.




Fig. 5: The ZomB protein specifically binds to the BOX region within the Ply encoding operon. (a) cartoon of the *ply* encoding operon with the *yebC* and *ply* genes, the SPN23F-locus tags of the neighbouring genes, and promoter and transcript length (black arrow) indicated. (b) EMSAs demonstrating the specificity of binding of the ZomB protein for two regions within the *ply* locus. The concentrations of ZomB used were 2.5, 5, 10, 20, 40 and 80nM.




Fig. 6: ZomB has a negative effect on the nasal colonisation of mice by *S. pneumoniae*. (a) Groups of C57Blk mice were inoculated intranasally with wild type *S. pneumoniae* or an isogenic ZomB mutant. At specific time points post colonisation the upper respiratory tract was lavaged with sterile PBS and the bacterial burdens in the lavage fluid quantified (a) and the lungs removed, homogenised and the bacterial burdens quantified to determine lower respiratory tract colonisation levels (b). The data from each mouse and sample are provided with the mean CFU +/- the standard error of the mean indicated. Statistical analysis was performed using a Kruskal-Wallis test with Dunn's Multiple Comparisons. * $P < 0.05$.

TABLES

Table 1: Primers used to construct mutants.

Amplification site	Primer Sequence
<i>ply</i> (LHS) forward	5' CCCTTGCTCTGGTTAAAAAAGAAGC 3'
<i>ply</i> (LHS) reverse	5' ATATTTTTGTTTCATATTTGCCATCTTCTACC 3'
<i>ery-ply</i> forward	5' GGTAAGAAGATGGCAAATATGAACAAAAATATAAAA 3'
<i>ery-ply</i> reverse	5' CTACCTGAGGTTATTTCTCCCGTT 3'
<i>ply</i> (RHS) forward	5' GAGGAAATAACCTCAGGTAGAAGATAAG 3'
<i>ply</i> (RHS) reverse	5' GATCACCTTTTTTAGCTGCTACATAG 3'
<i>zomB</i> (LHS) forward	5' TGCCCACTATTTTTATCTAGTTGCTTACC 3'
<i>zomB</i> (LHS) reverse	5' ATTTTTGTTTCATTGTTGTCATCGTTTTACCTC 3'
<i>ery-zomB</i> forward	5' CGATGACAACAATGAACAAAAATATAA 3'
<i>ery-zomB</i> reverse	5' CTTTTCCGGATTCTTATTTCTCCC 3'
<i>zomB</i> (RHS) forward	5' GGAGGAAATAAGAATCCGGAAAAG 3'
<i>zomB</i> (RHS) reverse	5' AATTAATTCCTGAATACAAGTTAACAAAATAG 3'

Table 2: Sample indices for sequencing.

Sample	Index 1 (i7)	Index 2 (i5)
WT1	CCGCGGTT	CTAGCGCT
WT2	TTATAACC	TCGATATC
WT3	GGAATTGG	CGTCTGCG
zomB1	AAGTCCAA	TACTCATA
zomB2	ATCCACTG	ACGCACCT
zomB3	GCTTGTCA	GTATGTTC

Table 3: Transcriptional differences between the *zomB* mutant relative to the wild type strain. The locus tags in bold indicate those encoded within the *ply* operon.

Locus Tag	Fold Change (Log2)	P values (adjusted)	Gene Product
SPN23F11770	1.8	2.3×10^{-5}	ABC-F family ATP-binding cassette domain-containing protein
SPN23F12440	1.1	9.3×10^{-3}	Plasmid mobilization relaxosome protein MobC
SPN23F12470	-7.1	7.8×10^{-113}	ZomB protein
SPN23F19450	-2.5	3.1×10^{-3}	MarR family transcriptional regulator
SPN23F19460	-2.7	1.3×10^{-30}	YebC DNA-binding transcriptional regulator
SPN23F19470	-4.8	4.4×10^{-49}	Pneumolysin
SPN23F19480	-4.9	4.1×10^{-38}	Hypothetical protein
SPN23F19490	-5.2	5.5×10^{-30}	Hypothetical protein
SPN23F19500	-5.0	6.4×10^{-24}	DUF4231 domain-containing protein